• 1
    Gubner R, August S, Ginsberg V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 221: 176182, 1951
  • 2
    Weinblatt ME, Fraser P: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 32: 15921596, 1989
  • 3
    Al-Awadhi A, Dale P, McKendry RJ: Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 20: 11211125, 1993
  • 4
    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 918, 1990
  • 5
    Shiroky J, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, Bykerk V, Kanji M, St-Pierre A, Robidoux L, Bourque L: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 36: 795803, 1993
  • 6
    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcón GS: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 121: 833841, 1994
  • 7
    Baggott JE, Morgan SL, Ha T, Alarcón GS, Koopman WJ, Krumdieck CL: Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 11 (Suppl 8): S101S105, 1993
  • 8
    Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312: 818822, 1985
  • 9
    Anderson PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized double-blind study. Ann Intern Med 103: 489496, 1985
  • 10
    Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 35: 138145, 1992
  • 11
    Alarcón GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ: Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis: evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33: 11561161, 1990
  • 12
    Moore S, Ruska K, Peters L, Olsen NJ: Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis. Immunol Invest 23: 355365, 1994
  • 13
    Olsen NJ, Teal GP, Brooks RH: IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions 34: 169171, 1991
  • 14
    Olsen NJ, Murray LM: Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 32: 378385, 1989
  • 15
    Olsen NJ, Callahan LF, Pincus T: Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 30: 481488, 1987
  • 16
    Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell 85: 307310, 1996
  • 17
    Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ: Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 38: 15811588, 1995
  • 18
    Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38: 10971106, 1995
  • 19
    Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 31: 167175, 1988
  • 20
    Wascher TC, Hermann J, Brezinschek HP, Brezinschek R, Wilders-Truschnig M, Rainer F, Krejs GJ: Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Invest 72: 535540, 1994
  • 21
    Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME: Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 33: 11491155, 1990
  • 22
    Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 35: 376384, 1992
  • 23
    Leroux JL, Damon M, Chavis C, Crastes de Paulet A, Blotman F: Effects of a single dose of methotrexate on 5- and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol 19: 863866, 1992
  • 24
    Hawkes JS, Cleland LG, Proudman SM, James MJ: The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 21: 5558, 1994
  • 25
    Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, Sherman M: Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: clinical and immunologic effects. Arthritis Rheum 33: 810820, 1990
  • 26
    Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L: Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 106: 497503, 1987
  • 27
    Kremer JM: The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 21: 15, 1994
  • 28
    Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M: Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 144: 195223, 1995
  • 29
    Hu SK, Mitcho YL, Oronsky AL, Kerwar SS: Studies on the effect of methotrexate on macrophage function. J Rheumatol 15: 206209, 1988
  • 30
    Connolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T: Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int J Immunopharmacol 10: 717728, 1988
  • 31
    Chang DM, Baptiste P, Schur PH: The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 17: 11481157, 1990
  • 32
    Segal R, Mozes E, Yaron M, Tartakovsky B: The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 32: 370377, 1989
  • 33
    Meyer FA, Yaron I, Mashiah V, Yaron M: Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 20: 238242, 1993
  • 34
    Brody M, Bohm I, Bauer R: Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1β to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 31: 667674, 1993
  • 35
    Furst DE: Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 34 (Suppl 2): 2025, 1995
  • 36
    Chang DM, Weinblatt ME, Schur PH: The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 19: 16781682, 1992
  • 37
    Thomas R, Carroll GJ: Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 36: 12441252, 1993
  • 38
    Williams AS, Punn YL, Amos N, Cooper AM, Williams BD: The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. Br J Rheumatol 34: 241245, 1995
  • 39
    Williams AS, Camilleri JP, Topley N, Williams BD: Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. J Pharmacol Toxicol Methods 32: 5358, 1994
  • 40
    Williams AS, Topley N, Amos N, Williams BD: Effect of three lipophilic methotrexate derivatives upon mediator release by lipopolysaccharide-stimulated rat peritoneal macrophages. J Pharm Pharmacol 46: 291295, 1994
  • 41
    Williams AS, Topley N, Williams BD: Effect of liposomally encapsulated MTX-DMPE conjugates upon TNFα and PGE2 release by lipopolysaccharide stimulated rat peritoneal macrophages. Biochim Biophys Acta 1225: 217222, 1994
  • 42
    Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM: Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 5: 298304, 1993
  • 43
    Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ: Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 34: 602609, 1995
  • 44
    Barrera P, Haagsma CJ, Boerbooms AMT, van Riel PLC, Borm GF, van de Putte LBA, van der Meer JWM: Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 34: 747755, 1995
  • 45
    Barrera P, Boerbooms AMT, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PNM, van de Putte LBA, van der Meer JWM: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36: 10701079, 1993
  • 46
    Crilly A, McInness IB, McDonald AG, Watson J, Capell HA, Madhok R: Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 22: 224226, 1995
  • 47
    Lacki JK, Klama K, Mackiewicz SH, Mackiewicz U, Muller W: Circulating interleukin-10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. Inflamm Res 44: 2426, 1995
  • 48
    Wascher TC, Hermann J, Brezinschek R, Brezinschek HP, Wilders-Truschnig M, Rainer F, Krejs GJ: Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest 24: 7375, 1994
  • 49
    Seitz M, Dewald B, Ceska M, Gerber N, Baggiolini M: Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int 12: 159164, 1992
  • 50
    Loetscher P, Dewald B, Baggiolini M, Seitz M: Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes: effects of anti-rheumatic drugs. Cytokine 6: 162170, 1994
  • 51
    Hershfield MS, Krodich NM: S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. Science 202: 757760, 1978
  • 52
    Kredich NM, Martin DV Jr: Role of S-adenosylhomocysteine in adenosine mediated toxicity in cultured mouse T lymphoma cells. Cell 12: 931938, 1977
  • 53
    Hershfield MS, Kurtzberg J, Aiyar VN, Suh EJ, Schiff R: Abnormalities in S-adenosylhomocysteine hydrolysis, ATP catabolism, and lymphoid differentiation in adenosine deaminase deficiency. Ann N Y Acad Sci 451: 7886, 1985
  • 54
    Palella TD, Schatz RA, Wilens TE, Fox IH: S-Adenosylhomocysteine accumulation and selective cytotoxicity in cultured T- and B-lymphocytes. J Lab Clin Med 100: 269278, 1982
  • 55
    Pike MC, Snyderman R: Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. Cell 28: 107114, 1982
  • 56
    Pike MC, Kredich NM, Snyderman R: Requirement of S-adenosyl-L-methionine-mediated methylation for human monocyte chemotaxis. Proc Natl Acad Sci USA 75: 39283932, 1978
  • 57
    Johnston JM, Kredich NM: Inhibition of methylation by adenosine in adenosine deaminase-inhibited, phytohemagglutinin-stimulated human lymphocytes. J Immunol 123: 97103, 1979
  • 58
    Furumitsu Y, Yukioka K, Kojima A, Yukioka M, Shichikawa K, Ochi T, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H: Levels of urinary polyamines in patients with rheumatoid arthritis. J Rheumatol 20: 16611665, 1993
  • 59
    Yukioka K, Wakitani S, Yukioka M, Furumitsu Y, Shichikawa K, Ochi T, Goto H, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H: Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. J Rheumatol 19: 689692, 1992
  • 60
    Flescher E, Bowlin TL, Talal N: Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol 87: 435437, 1992
  • 61
    Flescher E, Bowlin TL, Ballester A, Houk R, Talal N: Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis. J Clin Invest 83: 13561362, 1989
  • 62
    Miyasaka N, Nakamura T, Russell IJ, Talal N: Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 31: 109117, 1984
  • 63
    Miyasaka N, Murota N, Yamaoka K, Sato K, Yamada T, Nishido T, Okumura K: Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome. Clin Exp Immunol 65: 497505, 1986
  • 64
    Nesher G, Moore TL: The in vitro effects of methotrexate on peripheral blood mononuclear cells: modulation by methyl donors and spermidine. Arthritis Rheum 33: 954959, 1990
  • 65
    Nesher G, Moore TL, Dorner RW: In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann Rheum Dis 50: 637641, 1991
  • 66
    Krenitsky TA, Rideout JL, Chao EY, Koszalka GW, Gurney F, Crouch RC, Cohn NK, Wolberg G, Vinegar R: Imidazo[4,5-c]-pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents. J Med Chem 29: 138143, 1986
  • 67
    Jurgensen CH, Huber BE, Zimmerman TP, Wolberg G: 3-deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. J Immunol 144: 653661, 1990
  • 68
    Jurgensen CH, Wolberg G, Zimmerman TP: Inhibition of neutrophil adherence to endothelial cells by 3-deazaadenosine. Agents Actions 27: 398400, 1989
  • 69
    Fantone JC, Duque RE, Davis BH, Phan SH: 3-deazaadenosine inhibition of stimulus-response coupling in human polymorphonuclear leukocytes. J Leukoc Biol 45: 121128, 1989
  • 70
    Leonard EJ, Skeel A, Chiang PK, Cantoni GL: The action of the adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine, on phagocytic function of mouse macrophages and human monocytes. Biochem Biophys Res Commun 84: 102109, 1978
  • 71
    Zimmerman TP, Wolberg G, Duncan GS: Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential for cytolysis. Proc Natl Acad Sci USA 75: 62206224, 1978
  • 72
    Smith DM, Johnson JA, Turner RA: Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism. Int J Tissue React 13: 118, 1991
  • 73
    Sung SSJ, Silverstein SC: Inhibition of macrophage phagocytosis by methylation inhibitors: lack of correlation of protein carboxymethylation and phospholipid methylation with phagocytosis. J Biol Chem 260: 546554, 1985
  • 74
    Stopford CR, Wolberg G, Prus KL, Reynolds-Vaughn R, Zimmerman TP: 3-Deazaadenosine-induced disorganization of macrophage microfilaments. Proc Natl Acad Sci USA 82: 40604064, 1985
  • 75
    Zimmerman TP, Iannone M, Wolberg G: 3-Deazaadenosine: S-adenosylhomocysteine hydrolase-independent mechanism of action in mouse lymphocytes. J Biol Chem 259: 11221126, 1984
  • 76
    Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J: Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 76: 907912, 1985
  • 77
    Allegra CJ, Drake JC, Jolivet J, Chabner BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 82: 48814885, 1985
  • 78
    Baggott JE, Vaughn WH, Hudson BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 236: 193200, 1986
  • 79
    Ha T, Morgan SL, Vaughan WH, Baggott JE: Inhibition of adenosine deaminase and S-adenosyl homocysteine hydrolase by 5-aminoimidazole-4-carboxamide riboside. FASEB J 6: 12101215, 1992
  • 80
    Luhby AL, Cooperman JH: Aminoimidazole carboxamide excretion in vitamin B12 and folic acid deficiencies. Lancet 2: 13811382, 1962
  • 81
    Cronstein BN, Eberle MA, Gruber HE, Levin RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 88: 24412445, 1991
  • 82
    Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92: 26752682, 1993
  • 83
    Asako H, Kubes P, Baethge B, Wolf R, Granger DN: Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 16: 4556, 1992
  • 84
    Asako H, Wolf RE, Granger DN: Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. Gastroenterology 104: 3137, 1993
  • 85
    Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, Sambol B, Mullane K: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152: 58535859, 1994
  • 86
    Firestein GS, Bullough DA, Erion MD, Jimenez R, Ramirez-Weinhouse M, Barankiewicz J, Smith CW, Gruber HE, Mullane KM: Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: the role of selectins. J Immunol 154: 326334, 1995
  • 87
    Rosengren S, Bong GW, Firestein GS: Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J Immunol 154: 54445451, 1995
  • 88
    Cronstein BN, Naime D, Firestein GS: The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 38: 10401045, 1995
  • 89
    Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, Buckley MT, Carlin G, Cronstein BN: The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156: 19371941, 1996
  • 90
    Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ: Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 282: 197202, 1992
  • 91
    Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA: Aminophylline for methotrexate-induced neurotoxicity. Lancet 345: 544547, 1995
  • 92
    Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R: Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 78: 760770, 1986
  • 93
    Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R: Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 158: 11601177, 1983
  • 94
    Cronstein BN, Duguma L, Nicholls D, Hutchison A, Williams M: The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors which promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 85: 11501157, 1990
  • 95
    Salmon JE, Cronstein BN: Fcγ receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 145: 22352240, 1990
  • 96
    Cronstein BN, Levin RI, Philips MR, Hirschhorn R, Abramson SB, Weissmann G: Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 148: 22012206, 1992
  • 97
    Kammer GM, Birch RE, Polmar SH: Impaired immunoregulation in systemic lupus erythematosus: defective adenosine-induced suppressor T lymphocyte generation. J Immunol 130: 17061712, 1983
  • 98
    Schultz LA, Kammer GM, Rudolph SA: Characterization of the human T lymphocyte adenosine receptor: comparison of normal and systemic lupus erythematosus cells. FASEB J 2: 244250, 1988
  • 99
    Mandler R, Birch RE, Polmar SH, Kammer GM, Rudolph SA: Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 79: 75427546, 1982
  • 100
    Kammer GM, Rudolph SA: Regulation of human T lymphocyte surface antigen mobility by purinergic receptors. J Immunol 133: 32983302, 1984
  • 101
    Kammer GM, Smith JA, Mitchell R: Capping of human T-cell specific determinants: kinetics of capping and receptor reexpression and regulation by the cytoskeleton. J Immunol 130: 3844, 1983
  • 102
    Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C: Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156: 13491355, 1996
  • 103
    Parmely MJ, Zhou W-W, Edwards CK III, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 151: 389396, 1993
  • 104
    Bouma MG, Stad RK, van den Wildenberg FAJM, Buurman WA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153: 41594168, 1994
  • 105
    Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS: Inhibition of TNFα expression by adenosine: role of A3 adenosine receptors. J Immunol 156: 34353442, 1996
  • 106
    Le Moine O, Stordeur P, Schandené L, Marchant A, de Groote D, Goldman M, Devière J: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 156: 44084414, 1996
  • 107
    Firestein GS, Paine MM, Boyle DL: Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial collagenase gene expression. Arthritis Rheum 37: 193200, 1994
  • 108
    Boyle DL, Sajjadi FG, Firestein GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 39: 923930, 1996
  • 109
    Merrill JT, Coffey D, Shen C, Zakharenko O, Zhang HW, Lahita RG, Cronstein BN: Mechanisms of rheumatoid nodulosis: methotrexate-enhanced monocyte fusion requires protein synthesis and intact microtubules (abstract). Arthritis Rheum 38 (Suppl 9): S157, 1995